Shanghai Minimally Invasive Medical Devices (Group) Co., Ltd., founded in 1998, is a famous trademark in Shanghai, a group company dedicated to the development of cardiovascular interventional products/orthopedic medical devices, etc., and is known for its drug stents
Founded in 1998 as Shanghai MicroPort Medical Devices (Group) Co., Ltd., MicroPort is a leading high-end medical device group in China, headquartered in Zhangjiang Science City, Shanghai (1601 Zhangdong Road, Pudong New Area, Shanghai), China, and is committed to providing cost-effective medical solutions to the market through continuous innovation that can save and reshape patients' lives or improve their quality of life. MicroPort is a listed company in Hong Kong with stock code 00853.
MicroPort has more than 200 products on the market, covering ten major fields, including cardiovascular interventional products, orthopedic medical devices, aortic and peripheral vascular interventional products, electrophysiology medical devices, neurointerventional products, heart rhythm management products, diabetes and endocrine medical devices and surgery. MicroPort's products have entered more than 5,000 hospitals around the world, covering major markets such as Asia Pacific, Europe and the Americas. Worldwide, on average, every 15 seconds, a minimally invasive medical product is used to save a patient's life or improve their quality of life or help them give birth to a new life. Among them, the coronary drug stent product is the first domestic drug stent system, which has continued to maintain a leading domestic market share since its launch in 2004, and the world's first drug target-eluting stent system launched in 2014 has enabled MicroPort to complete the leap from a follower to a leader in the field of coronary stents. In the field of orthopedic joints, the market share of minimally invasive medical currently ranks fourth in the world.
MicroPort focuses on independent innovation, with a total of more than 1,700 authorized patents, a number of products have won the second prize of the National Science and Technology Progress Award and other national, provincial and ministerial honors, and has established production and R&D bases in Shanghai, Jiangsu, Zhejiang, Beijing, Shenzhen and Memphis in the United States. Through overseas mergers and acquisitions and joint ventures, MicroPort is gradually promoting its global industrial layout. The company currently employs more than 3,000 people, about one-third of whom are overseas employees.
Adhering to the management concept of "as subtle as possible, as vast as possible", MicroPort emphasizes people-oriented, and deeply integrates the pursuit of details and the persistence of innovation into the corporate genes. Through unremitting efforts, MicroPort hopes to build a global leading medical group for patients in the field of high-tech medicine represented by minimally trauma.
